Subclinical cardiovascular disease and it's improvement after long‐term <scp>TNF</scp>‐α inhibitor therapy in severe psoriatic patients

Herédi, Emese; Végh, Judit; Pogácsás, L.; Gáspár, Krisztián; Varga, József; Kincse, Gyöngyvér; Zeher, Margit; Szegedi, Andrea; Gaál, János

doi:10.1111/jdv.13649

Cited by 19 publications

(17 citation statements)

References 31 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Treatment of psoriasis patients with TNF-α inhibitors may also have beneficial effects on the development of atherosclerosis and components of the metabolic syndrome. Anti-TNF-α therapy in patients with severe psoriasis has been shown to improve subclinical cardiovascular disease (abnormalities in echocardiogram) [ 13 ], improve coronary microvascular function (determined by transthoracic Doppler echocardiography) [ 274 ], and attenuate the progression in coronary artery disease (assessed by coronary computed tomography) [ 275 ]. Treatment of patients with moderate to severe psoriasis with adalimumab for 6 months led to improvement in endothelial function (brachial artery reactivity) and carotid arterial stiffness [ 276 ].…”

Section: Effects Of Anti-psoriasis Therapies On Cardiovascular Commentioning

confidence: 99%

“…In some studies (particularly large-scale epidemiological studies), patients were classified as severe psoriasis if they required systemic therapy (including methotrexate, retinoid, cyclosporine, biological agents, or phototherapy) [ 3 , 11 , 12 ]. In other studies, severe psoriasis was defined in terms of Psoriasis Area and Severity Index score (for example, PASI > 15) [ 13 ], or body surface area involvement (for example, BSA > 10%) [ 14 , 15 ].…”

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Psoriasis and Cardiovascular Comorbidities: Focusing on Severe Vascular Events, Cardiovascular Risk Factors and Implications for Treatment

Lan

2017

IJMS

147

121

View full text Add to dashboard Cite

Psoriasis is a common and chronic inflammatory disease of the skin. It may impair the physical and psychosocial function of patients and lead to decreased quality of life. Traditionally, psoriasis has been regarded as a disease affecting only the skin and joints. More recently, studies have shown that psoriasis is a systemic inflammatory disorder which can be associated with various comorbidities. In particular, psoriasis is associated with an increased risk of developing severe vascular events such as myocardial infarction and stroke. In addition, the prevalence rates of cardiovascular risk factors are increased, including hypertension, diabetes mellitus, dyslipidemia, obesity, and metabolic syndrome. Consequently, mortality rates have been found to be increased and life expectancy decreased in patients with psoriasis, as compared to the general population. Various studies have also shown that systemic treatments for psoriasis, including methotrexate and tumor necrosis factor-α inhibitors, may significantly decrease cardiovascular risk. Mechanistically, the presence of common inflammatory pathways, secretion of adipokines, insulin resistance, angiogenesis, oxidative stress, microparticles, and hypercoagulability may explain the association between psoriasis and cardiometabolic disorders. In this article, we review the evidence regarding the association between psoriasis and cardiovascular comorbidities, focusing on severe vascular events, cardiovascular risk factors and implications for treatment.

show abstract

Section: Effects Of Anti-psoriasis Therapies On Cardiovascular Commentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

Psoriasis and Cardiovascular Comorbidities: Focusing on Severe Vascular Events, Cardiovascular Risk Factors and Implications for Treatment

Lan

2017

IJMS

147

121

View full text Add to dashboard Cite

show abstract

“…In other studies evaluating subclinical myocardial dysfunction with STE imaging in patients with psoriasis or PsA, the mean age of the subjects was 46, 41.1, 51.8, 41, and 51.5 years. 7,11,21,22,31 In the present study, although the subjects had no risk factors for CVD and were relatively young, myocardial dysfunction was still assessed using STE.…”

Section: Discussionmentioning

confidence: 94%

Subclinical Left Ventricular Dysfunction in Patients with Psoriasis Assessed Using Speckle Tracking Echocardiography

Karabay¹,

Çerman²,

Demіr³

et al. 2019

Turkiye Klinikleri J Dermatol

View full text Add to dashboard Cite

show abstract

“…Prolonged anti-TNF- α therapy has beneficial effects on the signs of subclinical cardiovascular disease in patients with severe psoriasis [ 27 ]. Studies have shown that, compared with nonbiologic disease-modifying antirheumatic drugs, TNF- α -blocking agents may contribute to the reduction of the risk of cardiovascular events in patients with rheumatoid arthritis [ 28 , 29 ].…”

Section: Discussionmentioning

confidence: 99%

Investigating the Mechanisms of Action of Depside Salt from Salvia miltiorrhiza Using Bioinformatic Analysis

Liu

2017

Evidence-Based Complementary and Alternative Medicine

View full text Add to dashboard Cite

Salvia miltiorrhiza is a traditional Chinese medicinal herb used for treating cardiovascular diseases. Depside salt from S. miltiorrhiza (DSSM) contains the following active components: magnesium lithospermate B, lithospermic acid, and rosmarinic acid. This study aimed to reveal the mechanisms of action of DSSM. After searching for DSSM-associated genes in GeneCards, Search Tool for Interacting Chemicals, SuperTarget, PubChem, and Comparative Toxicogenomics Database, they were subjected to enrichment analysis using Multifaceted Analysis Tool for Human Transcriptome. A protein-protein interaction (PPI) network was visualised; module analysis was conducted using the Cytoscape software. Finally, a transcriptional regulatory network was constructed using the TRRUST database and Cytoscape. Seventy-three DSSM-associated genes were identified. JUN, TNF, NFKB1, and FOS were hub nodes in the PPI network. Modules 1 and 2 were identified from the PPI network, with pathway enrichment analysis, showing that the presence of NFKB1 and BCL2 in module 1 was indicative of a particular association with the NF-κB signalling pathway. JUN, TNF, NFKB1, FOS, and BCL2 exhibited notable interactions among themselves in the PPI network. Several regulatory relationships (such as JUN → TNF/FOS, FOS → NFKB1 and NFKB1 → BCL2/TNF) were also found in the regulatory network. Thus, DSSM exerts effects against cardiovascular diseases by targeting JUN, TNF, NFKB1, FOS, and BCL2.

show abstract

Subclinical cardiovascular disease and it's improvement after long‐term TNF‐α inhibitor therapy in severe psoriatic patients

Abstract: Patients with severe psoriasis exhibit signs of subclinical cardiovascular disease compared to control, and prolonged anti-TNF-α therapy has a potentially beneficial effect on these signs.

Cited by 19 publications

References 31 publications

Psoriasis and Cardiovascular Comorbidities: Focusing on Severe Vascular Events, Cardiovascular Risk Factors and Implications for Treatment

Psoriasis and Cardiovascular Comorbidities: Focusing on Severe Vascular Events, Cardiovascular Risk Factors and Implications for Treatment

Subclinical Left Ventricular Dysfunction in Patients with Psoriasis Assessed Using Speckle Tracking Echocardiography

Investigating the Mechanisms of Action of Depside Salt from Salvia miltiorrhiza Using Bioinformatic Analysis

Contact Info

Product

Resources

About